new
   Indications for Seladelpar
505
Oct 21, 2025

Seladelpar is a novel peroxisome proliferator-activated receptor delta (PPAR-δ) agonist, which was approved in the United States in 2024 for the treatment of primary biliary cholangitis (PBC).

Indications for Seladelpar

Primary Biliary Cholangitis (PBC)

Seladelpar is indicated for use in combination with ursodeoxycholic acid (UDCA) for the treatment of adult patients with PBC who have an inadequate response to UDCA, or as monotherapy for patients who are intolerant to UDCA.

Its indication is based on the accelerated approval process, supported by the reduction in alkaline phosphatase (ALP) levels; however, its efficacy in improving survival or reducing hepatic decompensation events has not been confirmed.

Key Limitations

Contraindicated Populations: It is not recommended for patients with decompensated cirrhosis (e.g., ascites, variceal bleeding, hepatic encephalopathy).

Special Warnings: Vigilance is required regarding the risk of fractures (occurring in 4% of patients in clinical trials) and abnormal liver enzymes (transaminase elevation may occur at high doses).

Specifications and Properties of Seladelpar

Dosage Form Characteristics

Specification: Hard gelatin capsules containing 10mg of active ingredient per capsule, with an opaque light gray body and a dark blue cap. The cap is imprinted with "CBAY" and the body with "10".

Composition: The active ingredient is seladelpar lysine dihydrate, and the excipients include butylated hydroxytoluene, microcrystalline cellulose, etc. The capsule shell contains gelatin, titanium dioxide, and iron oxide colorants.

Pharmacological Properties

Pharmacological Action: It inhibits CYP7A1, a key enzyme in bile acid synthesis, by activating PPAR-δ, thereby reducing bile acid accumulation.

Metabolic Characteristics: It is mainly metabolized by CYP2C9, with a half-life of approximately 6 hours. 73.4% of the drug is excreted in urine (almost entirely as metabolites).

Storage Methods for Seladelpar

Routine Storage Conditions

Temperature: Store at 20°C to 25°C (68°F to 77°F); short-term storage at 15°C to 30°C (59°F to 86°F) is permitted.

Packaging: Supplied in original high-density polyethylene bottles with child-resistant caps, containing 30 capsules per bottle.

Usage Precautions

Light and Moisture Protection: Keep the bottle cap tightly sealed to prevent the capsules from absorbing moisture or being exposed to direct sunlight.

Expiration Management: It is recommended to use the capsules within 6 months after opening the bottle. If the capsules are deformed or leaking, they should be discarded immediately.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
RELATED ARTICLES
How to relieve the side effects of Gilteritinib (Xospata)?

Side effect management of Lazertinib requires targeted measures based on specific reaction types, with key focus on...

Friday, February 13th, 2026, 11:29
What are the side effects of Gilteritinib (Xospata)?

Gilteritinib (Xospata) is a FLT3 inhibitor. Its adverse reactions mainly involve the hematological system,...

Friday, February 13th, 2026, 11:01
Where to Buy Venetoclax Tablets

Venetoclax is a targeted medication used for the treatment of chronic lymphocytic leukemia/small lymphocytic...

Thursday, February 12th, 2026, 13:49
Indications of Venetoclax Tablets

Venetoclax is an innovative BCL‑2 inhibitor that plays an important role in the treatment of hematologic...

Thursday, February 12th, 2026, 13:46
RELATED MEDICATIONS
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
haiousales@gmail.com
Welcome To Consult
Seagull Pharmacy.,Ltd All rights reserved